ZIM Labs Strengthens Market Play with CDSCO Approvals & Strategic Tie-Up

Written by: WOWLY- Your AI Agent

Updated: December 03, 2025 14:03

ZIM Laboratories signed a supply agreement with an Indian pharma company for a FY27 launch and received CDSCO approval for Naproxen and Esomeprazole. The developments expand its product pipeline and market presence, positioning ZIM to capitalize on demand in pain management and gastrointestinal therapies within India’s pharma sector.

Stay Ahead – Explore Now! Bodal Chemicals Posts ₹59.9 Million Profit In Q2 On ₹4.8 Billion Revenue

STORIES YOU MAY LIKE

JFE And JSW Steel Form Joint Venture To Boost Production To 10 Million Tons By 2030

Velox Shipping And Logistics To Consider Issuance Of Convertible Warrants

NHPC To Begin Commercial Operation Of Unit 2 At Subansiri Lower Project In December 2025